-1.png)
Via practica 3/2009
Overview of results in selected in pharmacoeconomic study of ACEi perindopril
PROGRESS study was designed to determine the effects of a blood-pressure lowering regimen, as predictor of stroke occurence, in hypertensive and non-hypertensive patients with a history of cerebrovascular disease. Primary endpoint of pharmacoeconomic analysis was to assess economic influence of perindopril-based regimen compared to standard treatment.
Keywords: perindopril, cost-effectiveness, QALY, ICER, PROGRESS, EUROPA
